27
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      HMGB1 regulates erastin-induced ferroptosis via RAS-JNK/p38 signaling in HL-60/NRAS Q61L cells

      research-article

      Read this article at

      ScienceOpenPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Ferroptosis is emerging as a new form of regulated cell death driven by oxidative injury promoting lipid peroxidation in an iron-dependent manner. High mobility group box 1 (HMGB1) plays an important role in leukemia pathogenesis and chemotherapy resistance. The mechanisms of ferroptosis in tumor pathogenesis and treatment have been a recent research focus but the role of HMGB1 in regulating ferroptosis especially in leukemia still remains largely unknown. Here, we shown that HMGB1 is a critical regulator of eratin-induced ferroptosis in HL-60 cell line expressing NRAS Q61L (HL-60/NRAS Q61L). Erastin enhanced ROS levels, thereby promoting cytosolic translocation of HMGB1 and enhancing cell death. Knockdown of HMGB1 decreased erastin-induced ROS generation and cell death in an iron-mediated lysosomal pathway in HL-60/NRAS Q61L cells. Knockdown of HMGB1 or rat sarcoma (RAS), or pharmacological inhibition of JNK and p38 decreased TfR1 levels in HL-60/NRAS Q61L cells. Importantly, these data were further supported by our in vivo experiment, in which xenografts formed by HMGB1 knockdown HL-60/NRAS Q61L cells had lower PTGS2 and TfR1 expression than that in control mice. Taken together, these results suggest that HMGB1 is a novel regulator of ferroptosis via the RAS-JNK/p38 pathway and a potential drug target for therapeutic interventions in leukemia.

          Related collections

          Author and article information

          Journal
          Am J Cancer Res
          Am J Cancer Res
          ajcr
          American Journal of Cancer Research
          e-Century Publishing Corporation
          2156-6976
          2019
          01 April 2019
          : 9
          : 4
          : 730-739
          Affiliations
          [1 ] Department of Pediatrics, Xiangya Hospital, Central South University Changsha 410008, Hunan, People’s Republic of China
          [2 ] Department of Nuclear Medicine, Hunan Cancer Hospital Changsha 410008, Hunan, People’s Republic of China
          Author notes
          Address correspondence to: Liangchun Yang, Department of Pediatrics, Xiangya Hospital, Central South University, Changsha 410008, Hunan, People’s Republic of China. Tel: +86-073189753758; Fax: +86-073189753758; E-mail: yangliangchung@ 123456163.com
          Article
          PMC6511643 PMC6511643 6511643
          6511643
          31105999
          7c6c6552-4a46-448b-a718-160d9354953f
          AJCR Copyright © 2019
          History
          : 01 February 2019
          : 04 March 2019
          Categories
          Original Article

          ferroptosis,MAPK,transferrin receptor 1,HMGB1,acute myeloid leukemia

          Comments

          Comment on this article